8461203

2 known cases. View patent page →

Cases
2
Active
0
2 closed
Filed
2014
Top venue
D. New Jersey
2 cases

Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Limited et al.

consolidated/terminated
Docket:
2:14-cv-04467-ES-JAD
Filed:
2014-07-15
Terminated:
2015-04-22
Patents:84612036472431678088972622197851506826365083242757668730776510677651077895059845798885891828731963
π Jazz Pharmaceuticals, Inc.Δ Ranbaxy Laboratories LimitedΔ Ranbaxy Inc.

Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.

Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC

consolidated
Docket:
2:13-cv-00391-ES-JAD
Patents:8461203
π Jazz Pharmaceuticals, Inc.Δ Amneal Pharmaceuticals, LLC

Consolidated Xyrem patent litigation in the District of New Jersey into which numerous ANDA cases, including Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Ltd. (2:14-cv-04467), were consolidated for all purposes. The consolidation orders confirm the '203 patent litigation stream flowed into this broader case.